NDRA vs NUWE

ENDRA Life Sciences Inc. vs Nuwellis, Inc. — Valuation Comparison 2026

NDRA

Electromedical & Electrotherapeutic Apparatus
ENDRA Life Sciences Inc.
Quality
3.6
out of 10
Value Trap
39
LOW
Price
$5.50
Last close
Models
6/13
Active
VS

NUWE

Electromedical & Electrotherapeutic Apparatus
Nuwellis, Inc.
Quality
5.6
out of 10
Value Trap
39
LOW
Price
$0.77
Last close
Models
3/13
Active

Model-by-Model Comparison

ModelType NDRA Fair ValueNDRA Upside NUWE Fair ValueNUWE Upside
Bayesian DCF Intrinsic $1.47 -73.4% $0.65 -16.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $9.64 +75.3%
PWERM Option-Based $6.15 +11.8% $2.38 +207.7%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NDRA vs NUWE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NDRA vs NUWE — Which Stock Is More Undervalued?

NUWE scores higher with a 5.6/10 quality rating vs NDRA's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ENDRA Life Sciences Inc. (NDRA) and Nuwellis, Inc. (NUWE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NDRA currently trades at $5.50 with a QOC of 3.6/10, while NUWE trades at $0.77 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).